- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.01. | Chugai drops only AI-assisted antibody from pipeline but still holds high hopes for tech | 4 | FierceBiotech | ||
| 29.01. | Chugai Pharmaceutical FY2025 slides: Record profits amid pipeline evolution | 3 | Investing.com | ||
| 29.01. | Chugai: Rekordgewinn im Geschäftsjahr 2025 - Pipeline-Anpassung verunsichert Anleger | 3 | Investing.com Deutsch | ||
| 29.01. | Chugai Pharmaceutical: Rekordgewinne im Geschäftsjahr 2025, doch Aktie gibt nach | 3 | Investing.com Deutsch | ||
| CHUGAI PHARMACEUTICAL CO LTD ADR Aktie jetzt für 0€ handeln | |||||
| 29.01. | Chugai Pharmaceutical reports FY results | 2 | Seeking Alpha | ||
| 29.01. | Chugai Pharma FY25 Results Climb, Sees Growth In FY26 Core Profit, Revenues | 257 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) reported Thursday higher profit and revenues in fiscal 2025. The company further announced year-end dividends, and lower fiscal 2026... ► Artikel lesen | |
| 22.12.25 | Chugai Secures Regulatory Nod For Tecentriq In Thymic Carcinoma | 381 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) on Monday announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Tecentriq Intravenous Infusion for an... ► Artikel lesen | |
| 25.11.25 | Chugai Reports Positive Data From TEIEN Study Of Port Delivery System With Ranibizumab In NAMD & DME | 349 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) on Tuesday reported positive results from its phase I/II TEIEN study evaluating the Port Delivery System with Ranibizumab (PDS) in... ► Artikel lesen | |
| 25.11.25 | Chugai Pharmaceutical Teams With Biomy For Development Of AI-based Cancer Pathology Program | 403 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCY.PK), Tuesday announced a Memorandum of Understanding with Biomy, Inc., a provider of innovative services for pharmaceutical companies... ► Artikel lesen | |
| 06.11.25 | Rani Therapeutics announces $1.085 billion Chugai collaboration | 16 | Investing.com | ||
| 27.10.25 | Chugai acquires Renalys, enhancing its kidney disease portfolio | 3 | Pharmaceutical Technology | ||
| 24.10.25 | Chugai buys a kidney biotech; ICER targets rising launch prices | 4 | BioPharma Dive | ||
| 24.10.25 | Roche's Chugai strikes $200M M&A deal to take over IgAN asset in several Asian countries | 29 | FiercePharma | ||
| 24.10.25 | Chugai buys 'Asia lag' firm Renalys for $98m upfront | 3 | pharmaphorum | ||
| 24.10.25 | Chugai Pharmaceutical 9-month Net Income Rises | 396 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Chugai Pharmaceutical Co. reported, on a IFRS basis, nine month net income of 305.6 billion yen, up 3.3% from a year ago. Revenue was 911.6 billion yen,... ► Artikel lesen | |
| 23.10.25 | Roche axes 4 Chugai solid tumor assets in early-phase clearout | 10 | FierceBiotech | ||
| 17.10.25 | Licensing galore: Roche ties up with Hansoh on ADCs as Rani rounds out week with Chugai pact | 12 | FierceBiotech | ||
| 17.10.25 | Rani Therapeutics surges on Chugai licensing deal, private placement | 32 | Seeking Alpha | ||
| 17.10.25 | Rani Therapeutics: Aktie schießt nach potenziellem Milliarden-Deal mit Chugai in die Höhe | 38 | Investing.com Deutsch | ||
| 17.10.25 | Rani Therapeutics stock soars after inking $1 billion potential deal with Chugai | 12 | Investing.com |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TRULIEVE CANNABIS | 5,970 | +2,14 % | Trulieve Cannabis Corp.: Trulieve Completes Redemption of All US$368 Million 8.0% Senior Secured Notes due 2026 | TALLAHASSEE, Fla., Dec. 8, 2025 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis... ► Artikel lesen | |
| WEST PHARMACEUTICAL SERVICES | 206,70 | -1,85 % | Dividendenbekanntmachungen (28.01.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ANTERO MIDSTREAM CORPORATION US03676B1026 0,225 USD 0,1868 EUR CAL-MAINE FOODS INC US1280302027 0,719 USD 0,597 EUR CLOROX COMPANY US1890541097 1... ► Artikel lesen | |
| SHIONOGI | 18,600 | 0,00 % | Shionogi & Co. GAAP EPS of ¥188.00, revenue of ¥500B | ||
| KALA BIO | 0,375 | -0,74 % | KALA BIO, Inc. - 8-K, Current Report | ||
| CHARLOTTES WEB | 0,394 | +2,60 % | Charlotte's Web Holdings, Inc.: Charlotte's Web Reports Q3 2025 Results | Healthcare Focus, Product Innovation, and Cost Improvements
LOUISVILLE, Colo., Nov. 12, 2025 /PRNewswire/ - (TSX: CWEB) (OTC: CWBHF), Charlotte's Web Holdings,... ► Artikel lesen | |
| BEXIMCO PHARMACEUTICALS | 0,476 | 0,00 % | Beximco Pharma. - Order re Extension to Publish Financial Results | ||
| LUYE PHARMA | 0,292 | 0,00 % | LUYE PHARMA's Nanjing Luye Receives RMB285M Capital Injection | ||
| MIRUM PHARMACEUTICALS | 85,00 | 0,00 % | Mirum Pharmaceuticals Stumbles on Health Canada Approval | ||
| PERCHERON THERAPEUTICS | 0,004 | 0,00 % | Edison Group: Edison Issues Report on Percheron Therapeutics (PER) | London, United Kingdom--(Newsfile Corp. - November 27, 2025) - Edison issues report on Percheron Therapeutics (ASX: PER)We have refreshed our investment case for Percheron as the company heads into... ► Artikel lesen | |
| AYURCANN | 0,014 | 0,00 % | XFRA 3ZQ0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| AVANT BRANDS | 0,494 | -1,20 % | Avant Brands Inc.: Avant Brands Adopts Shareholder Rights Plan | KELOWNA, BC / ACCESS Newswire / January 9, 2026 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU0) ("Avant" or the "Company"), a leading producer of innovative and award-winning cannabis products... ► Artikel lesen | |
| KALBE FARMA | 0,051 | 0,00 % | KLBF to buyback shares, allocating IDR 250 billion: KLBF plans to repurchase shares worth IDR 250 billion over ... | ||
| EVEREST MEDICINES | 4,160 | -3,26 % | Everest Medicines Limited: Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis | TOKYO, Feb 6, 2026 - (ACN Newswire) - Everest Medicines today announced that China's National Medical Products Administration (NMPA) has approved VELSIPITY(R) (etrasimod arginine tablets) for the treatment... ► Artikel lesen | |
| KOBAYASHI PHARMACEUTICAL | 27,600 | -1,43 % | Dividendenbekanntmachungen (29.12.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADWAYS INC JP3121970002 6,35 JPY 0,0344 EUR AGC INC JP3112000009 105 JPY 0,5701 EUR AMERICAN TOWER CORPORATION US03027X1000 1... ► Artikel lesen | |
| SILO WELLNESS | 0,008 | -100,00 % | Silo Wellness Inc.: Silo Wellness Submits CSE Listing Statement for Review of Born Defense Proposed Change of Business | Eugene, Oregon and Toronto, Ontario--(Newsfile Corp. - September 28, 2025) - Silo Wellness Inc. (CSE: SILO) ("Silo" or the "Company"), to be renamed Born Defense Inc., is pleased to announce that it... ► Artikel lesen |
Das Unternehmen CHUGAI PHARMACEUTICAL CO LTD ADR kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell -6,72 % bei einem Aktienkurs von 22,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHUGAI PHARMACEUTICAL CO LTD ADR finden Sie auf Wallstreet Online.